KAZIA THERAPEUTICS LTD
Business
Kazia Therapeutics Ltd is an emerging oncology-focused biotechnology company engaged in pharmaceutical drug development, primarily developing brain-penetrant and tumor-targeted small-molecule therapeutics. Its main product candidates include Paxalisib, a PI3K/Akt/mTOR pathway inhibitor for gliomas, pediatric brain tumors and brain metastases, and EVT801, a selective VEGFR3 inhibitor for advanced solid tumors. Key business activities are organized around clinical development programs and collaborations across adult brain cancer, pediatric brain cancer, brain metastases and EVT801 oncology studies. Kazia conducts global clinical trials and partnerships with major research centers and distributes access through investigator-led studies, compassionate use programs and regulatory pathways across the U.S., Australia, Europe and other jurisdictions.
Summary from filing dated 2025-11-07
Financials
Latest annual snapshot (FY2025, period end 2025-06-30). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-20.70M |
| Total assets | $6.06M |
| Total liabilities | $14.36M |
| Stockholders' equity | — |
| Operating cash flow | — |